A Randomized, Single-blind, Parallel-group, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab Administered Subcutaneously to Healthy Adults in China

Trial Profile

A Randomized, Single-blind, Parallel-group, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab Administered Subcutaneously to Healthy Adults in China

Completed
Phase of Trial: Phase I

Latest Information Update: 16 May 2017

At a glance

  • Drugs Denosumab (Primary)
  • Indications Bone cancer; Bone disorders; Bone metastases; Breast cancer; Corticosteroid-induced osteoporosis; Male osteoporosis; Malignant hypercalcaemia; Non-small cell lung cancer; Osteogenesis imperfecta; Osteoporosis; Postmenopausal osteoporosis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Mar 2015 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 02 Sep 2014 Planned End Date changed from 1 Apr 2015 to 1 Feb 2015, as per ClinicalTrials.gov record.
    • 02 Sep 2014 Planned primary completion date changed from 1 Apr 2015 to 1 Feb 2015, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top